Ion Channel Pharmacology
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: closed (22 September 2024) | Viewed by 202
Special Issue Editors
Interests: patch clamp; physiology; pacemakers; sodium channels; patch-clamp electrophysiology; electrophysiology; cardiology; patch-clamp techniques; channelopathies
Interests: cardiac arrhythmia mechanisms; ion channels; atrial fibrillation; ventricular arrhythmias; pharmacology
Special Issue Information
Dear Colleagues,
We would like to draw your attention to a Special Issue of Pharmaceuticals. Ion channels are distributed throughout the human body and play vital roles in excitable but also in non-excitable cells. Consequently, channelopathies caused by the dysfunction of ion channel subunits or their interacting proteins can result in multiple and complex diseases and syndromes. So far, a high number of pharmacological tools have been developed, and their development is still ongoing to treat channelopathies. Some drugs block specific ion channels, such as the various classic Class I-IV anti-arrhythmic drugs, while others promote ion channel expression, trafficking, or function. Unfortunately, drugs can also have side effects since ion channels, for example sodium channels, are present in multiple organs, like brain and heart, making successful drug treatments complicated. In this Special Issue on “Ion Channel Pharmacology”, original research articles, review articles, or other article types related to old and new drug testing, side effects, or new target discovery for the treatment of all types of channelopathies are particularly welcome.
Dr. Arie O. Verkerk
Dr. Mathilde R. Rivaud
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
-
ion channels
- channelopathies
- ion channel pharmacology
- pharmacotherapy
- channelopathies
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
